Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bexsero and PCV13 Concomitantly With Routine Infant Vaccines
NCT03621670Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2018
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal infection, sponsored by GSK. Primary endpoints: Number of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1, Number of Participants Reporting Any Solicited Systemic Events After the First Vaccination Administered at Day 1 and 6 more. Started Jul 2018; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT03621670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03621670.